Sustained vascular contractile response induced by an R- and S-epimer of the ergot alkaloid ergocristine and attenuation by a noncompetitive antagonist.
Claviceps purpurea
artery
ergocristinine
phenoxybenzamine
Journal
Journal of animal science
ISSN: 1525-3163
Titre abrégé: J Anim Sci
Pays: United States
ID NLM: 8003002
Informations de publication
Date de publication:
01 Sep 2022
01 Sep 2022
Historique:
received:
21
04
2022
accepted:
30
06
2022
pubmed:
2
7
2022
medline:
24
9
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
Vasoconstriction is a known effect associated with ergot alkaloid consumption. The vascular contractile responses are often sustained for an extended period after exposure. Ergot alkaloids exist in two molecular configurations, the C-8-(R)-isomer (R-epimer) and the C-8-(S)-isomer (S-epimer). The sustained vascular contractile response to the R-epimers has been studied previously, unlike the S-epimers which are thought to be biologically inactive. Additionally, antagonists have been utilized to attenuate the vascular contraction associated with the R-epimers of ergot alkaloids utilizing ex vivo techniques. This study utilized an arterial tissue bath to examine and compare the sustained vascular contractile response attributed to ergocristine (R) and ergocristinine (S) using dissected bovine metatarsal arteries. The contractile blocking effect of a noncompetitive alpha-adrenergic antagonist, phenoxybenzamine (POB), was also investigated in precontracted arteries. Arteries (n = 6/epimer) were exposed to a single dose of ergocristine or ergocristinine (1 × 10-6 M in buffer). Each of the epimer doses was followed by a POB (1 × 10-3 M) or methanol (control) treatment at 90 min and the response was observed for another 90 min. Both epimers produced a sustained contractile response over the 180-min incubation period in the control groups. The R-epimer caused a greater sustained contractile response from 60 to 180 min post epimer exposure, compared to the S-epimer (P < 0.05, generalized estimating equations, independent t-test). Phenoxybenzamine caused a decrease in the contractile response induced by ergocristine and ergocristinine from 105 to 180 min, compared to the control (P < 0.05, generalized estimating equations, paired t-test). Overall, these results demonstrate the presence of a sustained vascular contractile response attributed to the R- and S-epimer of an ergot alkaloid with differences in contractile response between the epimers, suggesting differences in receptor binding mechanisms. Furthermore, this study demonstrated that a noncompetitive antagonist could attenuate the sustained arterial contractile effects of both ergot configurations ex vivo. Additional investigation into S-epimers of ergot alkaloids is needed. This research contributes to the understanding of the ergot epimer-vascular receptor binding mechanisms, which may support the investigation of different approaches of minimizing ergot toxicity in livestock. Ergot alkaloids cause blood vessels to contract when contaminated feed is consumed by animals. Vascular contraction often remains for a prolonged period and involves the binding of ergot to specific receptors in the blood vessels. This study assessed and compared the sustained contraction of cow arteries after exposure to two forms of an ergot alkaloid, namely, ergocristine and ergocristinine. The effects of a specific receptor blocker, phenoxybenzamine, on the vascular contraction induced by these forms were also examined. This study showed that both forms of ergot caused a sustained contraction of cow arteries but to different magnitudes. Differences in contraction could be related to differences in how each form of ergot binds to receptors. The receptor blocker decreased the sustained contractile response of both forms of ergot. Further understanding of how the different forms of ergot bind to receptors, and how to decrease the adverse effects, may help mitigate the toxic effects of ergotism.
Autres résumés
Type: plain-language-summary
(eng)
Ergot alkaloids cause blood vessels to contract when contaminated feed is consumed by animals. Vascular contraction often remains for a prolonged period and involves the binding of ergot to specific receptors in the blood vessels. This study assessed and compared the sustained contraction of cow arteries after exposure to two forms of an ergot alkaloid, namely, ergocristine and ergocristinine. The effects of a specific receptor blocker, phenoxybenzamine, on the vascular contraction induced by these forms were also examined. This study showed that both forms of ergot caused a sustained contraction of cow arteries but to different magnitudes. Differences in contraction could be related to differences in how each form of ergot binds to receptors. The receptor blocker decreased the sustained contractile response of both forms of ergot. Further understanding of how the different forms of ergot bind to receptors, and how to decrease the adverse effects, may help mitigate the toxic effects of ergotism.
Identifiants
pubmed: 35775420
pii: 6623923
doi: 10.1093/jas/skac235
pmc: PMC9492154
pii:
doi:
Substances chimiques
Ergolines
0
Ergot Alkaloids
0
Phenoxybenzamine
0TTZ664R7Z
ergocristine
3E58HO2T0U
Methanol
Y4S76JWI15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Natural Sciences and Engineering Research Council of Canada
Organisme : Western College of Veterinary Medicine
Organisme : The Saskatchewan Ministry of Agriculture-Agriculture Development Fund
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society of Animal Science.
Références
J Anim Sci. 2009 Jul;87(7):2437-47
pubmed: 19286813
J Anim Sci. 2018 Nov 21;96(11):4912-4922
pubmed: 30476153
Toxins (Basel). 2021 Oct 13;13(10):
pubmed: 34679017
J Anim Sci. 2010 Jan;88(1):408-15
pubmed: 19783700
J Agric Food Chem. 2015 Jul 29;63(29):6644-50
pubmed: 26134095
J Anim Sci. 2001 Aug;79(8):2202-9
pubmed: 11518230
Toxicology. 2011 Apr 11;282(3):112-21
pubmed: 21295106
Heliyon. 2020 Jun 30;6(6):e04336
pubmed: 32637710
J Anim Sci. 2017 Nov;95(11):5151-5160
pubmed: 29293720
J Anim Sci. 2007 Sep;85(9):2330-6
pubmed: 17504952
Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):120-9
pubmed: 2234096
Life Sci. 1993;53(14):PL223-8
pubmed: 8371626
Headache. 2006 Nov;46 Suppl 4:S171-81
pubmed: 17078849
Toxins (Basel). 2015 Jun 03;7(6):2024-50
pubmed: 26046699
Am J Vet Res. 1989 Feb;50(2):235-8
pubmed: 2719386
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30
pubmed: 18066532
Foods. 2019 May 01;8(5):
pubmed: 31052444
J Pharmacol Exp Ther. 2013 Dec;347(3):645-59
pubmed: 24049061
Toxins (Basel). 2021 Dec 23;14(1):
pubmed: 35050986
Toxins (Basel). 2021 Dec 31;14(1):
pubmed: 35050999
J Anim Sci. 2011 Sep;89(9):2944-9
pubmed: 21512122
J Anim Sci. 1993 Oct;71(10):2708-13
pubmed: 7901191
Toxins (Basel). 2015 Jul 27;7(8):2801-21
pubmed: 26226000
Br J Pharmacol. 1974 Jul;51(3):441-6
pubmed: 4155973
Br J Pharmacol. 2003 May;139(2):424-34
pubmed: 12770948
Toxins (Basel). 2020 Oct 26;12(11):
pubmed: 33114663
J Anim Sci. 2020 Jul 1;98(7):
pubmed: 32629472
J Anim Sci. 2014 Mar;92(3):1213-8
pubmed: 24492541
Sci Rep. 2020 Sep 21;10(1):15383
pubmed: 32958803
J Pharmacol Exp Ther. 2005 Aug;314(2):891-905
pubmed: 15857948
Toxins (Basel). 2016 Sep 22;8(10):
pubmed: 27669299
J Anim Sci. 2002 Jun;80(6):1616-22
pubmed: 12078743
Mol Nutr Food Res. 2012 Mar;56(3):475-85
pubmed: 22147614